Gut microbiota and its metabolites such as short chain fatty acids (SCFA),
lipopolysaccharides (LPS), and trimethylamine-N-oxide (TMAO) impact cardiovascular …

The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing recently and has
become one of the most common clinical liver diseases. Since the pathogenesis of NAFLD …

Bile acid synthesis is the most significant pathway for catabolism of cholesterol and for
maintenance of whole body cholesterol homeostasis. Bile acids are physiological …

Multiphase pathological processes involve in Type 2 diabetes (T2DM)‐induced
nonalcoholic fatty liver disease (NAFLD). However, the therapies are quite limited. In the …

Bile acids participate in the intestinal emulsion, digestion, and absorption of lipids and fat-
soluble vitamins. When present in high concentrations, as in cholestatic liver diseases, bile …

Inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis
(UC), is characterized as a chronic and recurrent inflammatory disease whose pathogenesis …

The bile acid receptor FXR has emerged as a bona fide drug target for chronic cholestatic
and metabolic liver diseases, ahead of all non-alcoholic fatty liver disease (NAFLD). FXR is …

Non-alcoholic fatty liver disease (NAFLD) is recognized as the most frequent classification of
liver disease around the globe. Along with the sequencing technologies, gut microbiota has …

Fatty liver disease (FLD), including nonalcoholic fatty liver disease (NAFLD) and alcoholic
fatty liver disease (AFLD), is a serious chronic metabolic disease that affects a wide range of …

Abstract The BA-responsive GPCRs S1PR2 and TGR5 are almost ubiquitously expressed in
human and rodent tissues. In the liver, S1PR2 is expressed in all cell types, while TGR5 is …